ATAI is currently priced at $5.67. The technical outlook is "Strong Buy" based on moving average alignment, RSI, and MACD signals.
Technical & fundamental data as of Jul 14, 2026.
Open?$4.98
High?$5.77
Low?$4.97
Prev. Close?$4.97
Volume?11.5M
Avg. Volume?N/A
VWAP?$5.54
Bid / Ask
Bid?$4.86 × 100
Ask?$6.47 × 100
Spread?$1.61
Midpoint?$5.67
Valuation & Ratios
Market Cap?1.8B
Shares Out?368.2M
Float?298.7M
Float %?81.4%
P/E Ratio?N/A
P/B Ratio?N/A
EPS?N/A
Dividend?N/A
Ex-Dividend?N/A
News
Profile
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.